VX-702

AdipoGen Life Sciences
Product Code: SYN-1093
CodeSizePrice
SYN-1093-M100100 mgEnquire
Quantity:
SYN-1093-M0011 mg£69.00
Quantity:
SYN-1093-M0055 mg£80.00
Quantity:
SYN-1093-M01010 mg£92.00
Quantity:
SYN-1093-M05050 mg£268.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
-20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
VX702
Appearance:
Solid.
CAS:
745833-23-2
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H303, H317, H333
InChi:
InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)
InChiKey:
FYSRKRZDBHOFAY-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 745833-23-2. Formula: C19H12F4N4O2. MW: 404.3. The kinases called p38 MAP kinases (MAPKs) are intracellular, soluble serine-threonine kinases which belong to a large family of proteins that include the extracellular regulated kinases (ERKs) and c-Jun N-terminal kinases (JNKs). So far four p38 isoforms have been identified, namely p38alpha, p38beta, p38gamma and p38delta, a.k.a. p38-alpha (MAPK14), -beta (MAPK11), -gamma (MAPK12 / ERK6), and -delta (MAPK13 / SAPK4). The ubiquitously expressed s p38alpha has been the most extensively studied and is believed to be the most physiologically relevant in the regulation of the inflammatory response. The role of the three other isoforms is not currently well understood, however their primary sites of expression are known. Similar to p38alpha, p38beta is also ubiquitously expressed, while p38gamma is expressed predominately in skeletal muscle and p38delta is expressed primarily in the lung, kidney, testis, small intestine and pancreas. The small molecule inhibitor VX-702 is a potent p38 kinase family inhibitor that has been studied for its effects on inflammation and the inflammatory response. VX-702 dose-dependently inhibited the production o IL-6, IL-1beta and TNFalpha (IC(50) = 59, 122 and 99ng/ml, respectively), and in anti-platelet aggregation assays, pre-incubation of platelets with VX-702 (1µM)completely or partially inhibited platelet agonist induced p38 activation (IC(50) = 4 to 20nM). More recently VX-702 has been studied as a potential treatment for rheumatoid arthritis (RA). VX-702 appears to be most effective against MAPK14, followed by MAPK11 and the remaining members of the family, however exact in vitro IC(50) values have not been published. However a large amount of data is available for in vitro growth inhibition assays where VX-702 exhibits poptent activity, having low IC(50) values beginning at ~16nM and ending at < 400µM for the numerous cell lines tested.
Molecular Formula:
C19H12F4N4O2
Molecular Weight:
404.3
Package Type:
Plastic Vial
Precautions:
P261, P272, P280, P302, P352, P333, P313, P321, P363, P501
Product Description:
The kinases called p38 MAP kinases (MAPKs) are intracellular, soluble serine-threonine kinases which belong to a large family of proteins that include the extracellular regulated kinases (ERKs) and c-Jun N-terminal kinases (JNKs). So far four p38 isoforms have been identified, namely p38alpha, p38beta, p38gamma and p38delta , a.k.a. p38-alpha (MAPK14), -beta (MAPK11), -gamma (MAPK12 / ERK6), and -delta (MAPK13 / SAPK4). The ubiquitously expressed s p38alpha has been the most extensively studied and is believed to be the most physiologically relevant in the regulation of the inflammatory response. The role of the three other isoforms is not currently well understood, however their primary sites of expression are known. Similar to p38alpha, p38beta is also ubiquitously expressed, while p38gamma is expressed predominately in skeletal muscle and p38delta is expressed primarily in the lung, kidney, testis, small intestine and pancreas. The small molecule inhibitor VX-702 is a potent p38 kinase family inhibitor that has been studied for its effects on inflammation and the inflammatory response. VX-702 dose-dependently inhibited the production o IL-6, IL-1beta and TNFalpha (IC(50) = 59, 122 and 99ng/ml, respectively), and in anti-platelet aggregation assays, pre-incubation of platelets with VX-702 (1µM)completely or partially inhibited platelet agonist induced p38 activation (IC(50) = 4 to 20nM). More recently VX-702 has been studied as a potential treatment for rheumatoid arthritis (RA). VX-702 appears to be most effective against MAPK14, followed by MAPK11 and the remaining members of the family, however exact in vitro IC(50) values have not been published. However a large amount of data is available for in vitro growth inhibition assays where VX-702 exhibits poptent activity , having low IC(50) values beginning at ~16nM and ending at < 400µM for the numerous cell lines tested.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation: A. Kuliopulos, et al.; Thromb. Haemost. 92, 1387 (2004) | Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome: C. Ding; Curr. Opin. Investig. Drugs 7, 1020 (2006)

Related Products

Product NameProduct CodeSupplier 
SB202190AG-CR1-0028AdipoGen Life Sciences Summary Details